AGIHO癌症患者COVID-19管理指南2021更新:诊断、病毒排毒、疫苗与治疗
德国血液与肿瘤内科学会感染病工作组(AGIHO)基于证据医学标准批判性综述现有数据,更新癌症患者COVID-19管理指南,聚焦快速诊断、病毒排毒、疫苗接种和治疗四个临床重要议题,指出血液恶性肿瘤患者为重症COVID-19高危人群。
要点
- 血液恶性肿瘤患者是重症COVID-19高危人群,需重点关注。
- 指南更新聚焦快速诊断、病毒排毒、疫苗接种和治疗四个议题。
- 更新基于证据医学标准批判性综述现有数据制定推荐。
核心结论
- AGIHO基于证据医学标准更新癌症患者COVID-19管理推荐,涵盖诊断、病毒排毒、疫苗和治疗。
研究设计与样本
- 由德国血液与肿瘤内科学会感染病工作组(AGIHO)制定,采用证据医学标准批判性综述现有数据。
主要发现
- 癌症患者尤其是血液恶性肿瘤患者被确定为重症COVID-19高危人群。
- 自上一版指南发布后研究持续深入,疫苗接种研究领域出现新的重要数据。
临床怎么用
- 临床可参照该更新推荐管理癌症患者的COVID-19快速诊断、病毒排毒、疫苗接种和治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The worldwide spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious coronavirus disease (COVID-19) has posed a unique challenge to medical staff, patients and their families. Patients with cancer, particularly those with haematologic malignancies, have been identified to be at high risk to develop severe COVID-19. Since publication of our previous guideline on evidence-based management of COVID-19 in patients with cancer, research efforts have continued and new relevant data has come to light, maybe most importantly in the field of vaccination studies. Therefore, an update of our guideline on several clinically important topics is warranted. Here, we provide a concise update of evidence-based recommendations for rapid diagnostics, viral shedding, vaccination and therapy of COVID-19 in patients with cancer. This guideline update was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology by critically reviewing the currently available data on these topics applying evidence-based medicine criteria.
引用
- Giesen N, Sprute R, Rüthrich M, et al. 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer. 2021. PMID: 33676266. doi:10.1016/j.ejca.2021.01.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。